Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVJW0S)

Drug Name
AT-406 Drug Info
Synonyms
1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143
Indication
Disease Entry ICD 11 Status REF
Squamous head and neck cell carcinom 2D60.0 Phase 3 [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Lymphoma 2A80-2A86 Phase 1/2 [3]
Acute myeloid leukaemia 2A60 Phase 1 [4]
Cross-matching ID
PubChem CID
25022340
CAS Number
CAS 1071992-99-8
TTD Drug ID
DMVJW0S

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting X-linked inhibitor of apoptosis protein (XIAP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Birinapant DM6PBUM Lymphoma 2A80-2A86 Phase 2 [6]
Phenoxodiol DMBUJVX Ovarian cancer 2C73 Phase 1/2 [7]
APG-1387 DMLEKUY Haematological malignancy 2B33.Y Phase 1 [8]
HGS-1029 DMS9WXG Haematological malignancy 2B33.Y Phase 1 [9]
GDC-0152 DM1B3UM Obesity 5B81 Phase 1 [10]
PMID25980951-Compound-6 DMVSW5N N. A. N. A. Patented [11]
PMID25980951-Compound-27 DMXAH9F N. A. N. A. Patented [11]
PMID25980951-Compound-43 DMTJRCS N. A. N. A. Patented [11]
PMID25980951-Compound-1 DMYPT2H N. A. N. A. Patented [11]
PMID25980951-Compound-44 DMS5896 N. A. N. A. Patented [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cellular inhibitor of apoptosis 2 (BIRC3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID25980951-Compound-27 DMXAH9F N. A. N. A. Patented [11]
PMID25980951-Compound-43 DMTJRCS N. A. N. A. Patented [11]
PMID25980951-Compound-1 DMYPT2H N. A. N. A. Patented [11]
PMID25980951-Compound-44 DMS5896 N. A. N. A. Patented [11]
AZD5582 DMPIHN6 Discovery agent N.A. Investigative [12]
Drug(s) Targeting Inhibitor of apoptosis protein (hIAP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LCL161 DMTM4QA Multiple myeloma 2A83 Phase 2 [13]
APG-1387 DMLEKUY Haematological malignancy 2B33.Y Phase 1 [14]
Drug(s) Targeting Cellular inhibitor of apoptosis 1 (BIRC2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Birinapant DM6PBUM Lymphoma 2A80-2A86 Phase 2 [6]
PMID25980951-Compound-6 DMVSW5N N. A. N. A. Patented [11]
PMID25980951-Compound-27 DMXAH9F N. A. N. A. Patented [11]
PMID25980951-Compound-43 DMTJRCS N. A. N. A. Patented [11]
PMID25980951-Compound-1 DMYPT2H N. A. N. A. Patented [11]
PMID25980951-Compound-44 DMS5896 N. A. N. A. Patented [11]
PMID25980951-Compound-3 DMPSWXU N. A. N. A. Patented [11]
PMID25980951-Compound-4 DM9RZSH N. A. N. A. Patented [11]
PMID25980951-Compound-21 DMIE0MR N. A. N. A. Patented [11]
PMID25980951-Compound-42 DM8XESD N. A. N. A. Patented [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cellular inhibitor of apoptosis 1 (BIRC2) TTQ5LRD BIRC2_HUMAN Inhibitor [5]
Cellular inhibitor of apoptosis 2 (BIRC3) TTIRY6K BIRC3_HUMAN Inhibitor [5]
Inhibitor of apoptosis protein (hIAP) TTS74QB XIAP_HUMAN; BIRC2_HUMAN; BIRC3_HUMAN; BIRC1_HUMAN; BIRC7_HUMAN; BIRC5_HUMAN Modulator [4]
X-linked inhibitor of apoptosis protein (XIAP) TTR7B60 XIAP_HUMAN Inhibitor [5]

References

1 ClinicalTrials.gov (NCT04459715) A Study of Debio 1143 (Xevinapant) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy. U.S. National Institutes of Health.
2 Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.
3 ClinicalTrials.gov (NCT02022098) Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial. U.S. National Institutes of Health.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7729).
5 Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51.
6 cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood. 2014 Apr 17;123(16):2562-72.
7 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
8 XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.Theranostics. 2018 Feb 5;8(6):1494-1510.
9 Clinical pipeline report, company report or official report of Aegera Therapeutics Inc.
10 Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem. 2012 May 10;55(9):4101-13.
11 Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
12 Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). J Med Chem. 2013 Dec 27;56(24):9897-919.
13 National Cancer Institute Drug Dictionary (drug id 670651).
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)